Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Published:2024-06 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Cordes Lisa M.,Karzai Fatima,Madan Ravi A.^ORCID

Publisher

Elsevier BV

Reference5 articles.

1. Xtandi (enzalutamide) package insert;Pharma,2023

2. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer;Freedland;N Engl J Med,2023

3. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer;Madan;J Immunother Cancer,2021

4. Enzalutamide and quality of life in biochemically recurrent prostate cancer;Freedland;NEJM Evid,2023

5. Outcomes of men with high-risk biochemically recurrent prostate cancer who suspend enzalutamide monotherapy treatment in the phase 3 EMBARK study;Shore;J Clin Oncol,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP